Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer

BACKGROUND: Anaplastic lymphoma kinase (ALK) fusion genes are found in 3%–5% of non‐small cell lung cancers (NSCLCs). ALK inhibitors show a very high response rate to ALK‐positive NSCLCs. However, the emergence of acquired resistance is inevitable. In this study, we investigated the drugs for overco...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Ken, Seto, Yosuke, Okada, Koutaroh, Uematsu, Shinya, Uchibori, Ken, Tsukahara, Mika, Oh‐hara, Tomoko, Fujita, Naoya, Yanagitani, Noriko, Nishio, Makoto, Okubo, Kenichi, Katayama, Ryohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049522/
https://www.ncbi.nlm.nih.gov/pubmed/31943796
http://dx.doi.org/10.1111/1759-7714.13299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049522/
https://www.ncbi.nlm.nih.gov/pubmed/31943796
http://dx.doi.org/10.1111/1759-7714.13299

Ejemplares similares